Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579020 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates
A Phase 2 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT00579020 is a Phase 2 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 144 participants.
The verdict
NCT00579020, a Phase 2 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.
Interventions
- DRUG Moxifloxacin/dexamethasone phosphate ophthalmic solution
- DRUG Moxifloxacin ophthalmic solution 0.5%
- DRUG Dexamethasone phosphate solution, 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579020
The ClinicalTrials.gov registry entry for NCT00579020 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin/dexamethasone phosphate ophthalmic solution is the first listed.
NCT00579020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00579020 about?
NCT00579020 is a clinical study titled "A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates". The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.
What is the current status of trial NCT00579020?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2007-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00579020?
The interventions under investigation include: Moxifloxacin/dexamethasone phosphate ophthalmic solution (DRUG), Moxifloxacin ophthalmic solution 0.5% (DRUG), Dexamethasone phosphate solution, 0.1% (DRUG).
Who is sponsoring clinical trial NCT00579020?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.